- |||||||||| 5-fluorouracil / Generic mfg.
Retrospective data, Journal, Metastases: Patients with Advanced Pancreatic Cancer Treated with Mistletoe and Hyperthermia in Addition to Palliative Chemotherapy: A Retrospective Single-Center Analysis. (Pubmed Central) - Oct 28, 2023 In total, 206 consecutive patients were included in the study, whereof 142 patients (68.9%) received palliative chemotherapy (gemcitabine/nab-paclitaxel 33.8%; FOLFIRINOX 35.9%; gemcitabine 30.3%) while the remainder were treated with best supportive and integrative care...A total of 107/142 patients (86.3%) died during the observation period, whereby survival times differed significantly depending on the additional use of integrative mistletoe or hyperthermia: chemotherapy alone 8.6 months (95% CI 4.7-15.4), chemotherapy and only mistletoe therapy 11.2 months (95% CI 7.1-14.2), or a combination of chemotherapy with mistletoe and hyperthermia 18.9 months (95% CI 15.2-24.5). While the survival times observed for patients with advanced pancreatic cancer receiving chemotherapy alone are consistent with pivotal phase-III studies and German registry data, we found significantly improved survival using additional mistletoe and/or hyperthermia.
- |||||||||| Cotellic (cobimetinib) / Exelixis, Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Metastases: MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - Oct 27, 2023 P1/2, N=410, Active, not recruiting, While the survival times observed for patients with advanced pancreatic cancer receiving chemotherapy alone are consistent with pivotal phase-III studies and German registry data, we found significantly improved survival using additional mistletoe and/or hyperthermia. Recruiting --> Active, not recruiting
- |||||||||| Modufolin (arfolitixorin) / Isofol Medical, Solasia
Trial completion, Combination therapy, Metastases: AGENT: A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 26, 2023 P3, N=490, Completed, Trial completion date: Jul 2027 --> Oct 2027 Active, not recruiting --> Completed
- |||||||||| leucovorin calcium / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Oct 25, 2023 P2, N=134, Recruiting, Trial completion date: Nov 2023 --> Feb 2024 | Trial primary completion date: Nov 2023 --> Feb 2024 Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025
- |||||||||| leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date: Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism (clinicaltrials.gov) - Oct 25, 2023 P2, N=80, Recruiting, Active, not recruiting --> Recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jan 2025 Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025
- |||||||||| monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Oct 24, 2023 P1/2, N=383, Active, not recruiting, Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024 Trial completion date: Jun 2023 --> Sep 2024
- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. (clinicaltrials.gov) - Oct 23, 2023 P3, N=202, Active, not recruiting, Trial completion date: Jun 2023 --> Sep 2024 Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Jun 2024 | Trial primary completion date: Oct 2022 --> Jun 2023
- |||||||||| Avastin (bevacizumab) / Roche
Journal: FOLFIRI-bevacizumab-induced acute toxic leukoencephalopathy. (Pubmed Central) - Oct 23, 2023 ATL is mostly reversible, but the progression of neurologic symptoms was also reported. The diagnosis and cessation of the responsible agent are important in management.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal, BRCA Biomarker, Circulating tumor DNA, Epigenetic controller: Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection. (Pubmed Central) - Oct 23, 2023 P2 However, the association between the thrombocytopenia regimen and previous fluorouracil, leucovorin, oxaliplatin, and docetaxel regimens needs further study. Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of pati-ents with borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker.
- |||||||||| AB598 / Arcus Biosci
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov) - Oct 23, 2023 P1, N=81, Recruiting, Detection of DDR gene mutations from plasma ctDNA at baseline was associated with better survival outcomes of pati-ents with borderline resectable pancreatic ductal adenocarcinoma treated with neoadjuvant mFOLFIRINOX and may be a prognostic biomarker. Trial completion date: Nov 2025 --> Aug 2025 | Trial primary completion date: Nov 2025 --> Aug 2025
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations. (Pubmed Central) - Oct 21, 2023 Therefore, an expert consensus conference was held on March 2023 in Guangzhou, China to review current practices regarding HAIC treatment in patients with HCC and develop widely accepted statements and recommendations. In this article, the latest evidence of HAIC was systematically summarized and the final 22 expert recommendations were proposed, which incorporate the assessment of candidates for HAIC treatment, procedural technique details, therapeutic outcomes, the HAIC-related complications and corresponding treatments, and therapeutic scheme management.
- |||||||||| Ampligen (rintatolimod) / AIM ImmunoTech
Trial completion date, Trial primary completion date: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC (clinicaltrials.gov) - Oct 19, 2023 P2, N=90, Recruiting, In this article, the latest evidence of HAIC was systematically summarized and the final 22 expert recommendations were proposed, which incorporate the assessment of candidates for HAIC treatment, procedural technique details, therapeutic outcomes, the HAIC-related complications and corresponding treatments, and therapeutic scheme management. Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Nov 2026 --> Jun 2027
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Metastases: BTCRC-GI15-015: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 16, 2023 P2, N=39, Completed, Trial completion date: Jan 2027 --> Nov 2023 Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023
- |||||||||| Review, Journal: Exosomes: Emerging Modulators of Pancreatic Cancer Drug Resistance. (Pubmed Central) - Oct 14, 2023
The most used therapy is gemcitabine, alone or in combination with nanoparticle albumin-bound paclitaxel (nab-paclitaxel), and the multidrug FOLFIRINOX...This review illustrates the role of exosomes in PaC drug resistance. This manuscript first provides an overview of the pharmacological approaches used in PaC and, in the last part, focuses on the mechanisms exploited by the exosomes released by cancer cells to induce drug resistance.
- |||||||||| veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion, Trial completion date, Metastases: NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Oct 12, 2023 P2, N=363, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Sep 2023
- |||||||||| Herzuma (trastuzumab-pkrb) / Nippon Kayaku, Mundipharma, Celltrion, Teva
Trial completion, Trial completion date, Trial primary completion date, Pan tumor: KCSG-HB19-14: Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy (clinicaltrials.gov) - Oct 11, 2023 P2, N=36, Completed, Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Sep 2023 Recruiting --> Completed | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Sep 2022 --> Jun 2023
- |||||||||| Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Clinical and cost-effectiveness analysis of mFOLOFX6 with or without a targeted drug among patients with metastatic colorectal cancer: inverse probability of treatment weighting. (Pubmed Central) - Oct 11, 2023 This study investigated the cost-effectiveness and quality of life (QoL) within 1 year of receiving mFOLOFX6 with or without a targeted drug (bevacizumab or ramucirumab) as second-line treatment among patients with metastatic colorectal cancer (mCRC) following the failure of FOLFIRI + bevacizumab as first-line treatment...Addition of a targeted drug to the second-line mFOLOFX6 regimen not only improved the patients' QoL but was also more cost effective when the willingness-to-pay threshold was set at US$33,004 (the per capita gross domestic product of Taiwan). These patients should be reimbursed for these targeted agents by the National Health Insurance scheme in Taiwan.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan (Exhibition area) - Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_905; In western countries where HPV+ OPC prevalence is high, induction TPF response rate in locally advanced HNSCC is around 70%; Erbitux and TP (Argiris in JCO2008) response rate is 86%...In our previous study from unresectable stage IVA & IVB betal-nuts related HNSCC patients in ASCO2023, flexible chemotherapy backbones, such as TP/DP-HDFL(weekly docetaxel or paclitaxel with cisplatin and 24-hr high dose 5-fluorouracil/leucovorin infusion) with Biotherapy(EGFR or VEGFR-targeting)or Bio-immunotherapy had encouraging induction response with favorable toxicity to conversion surgery or definite CCRT...Aggressive induction therapy followed by mini-invasive surgery and then adjuvant CCRT with maintenance UFUR might be administered in selected patients with high induction response. Encouraging outcomes have been shown by sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan.
|